{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:19:15Z","timestamp":1791242355316,"version":"4.1.0"},"reference-count":30,"publisher":"American Society of Hematology","issue":"22","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11,28]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Hemostatic imbalances are frequent in patients with cancer. Although cancer-associated thrombotic complications have been well characterized, data on bleeding events in patients with cancer are sparse. Therefore, we aimed to investigate the incidence, risk factors, and impact on prognosis of bleeding events in patients with cancer initiating systemic anticancer therapies in a prospective cohort study, the Vienna Cancer, Thrombosis, and Bleeding Study. The primary study outcome was defined as clinically relevant bleeding (CRB), comprising major bleeding (MB) and clinically relevant nonmajor bleeding. In total, 791 patients (48% female), with median age of 63 years (interquartile range [IQR], 54-70), with various cancer types, 65.5% stage IV, were included. Over a median follow-up of 19 months (IQR, 8.7-24.0), we observed 194 CRB events in 139 (17.6%) patients, of which 42 (30.0%) were tumor related, 64 (46.0%) gastrointestinal, and 7 (5.0%) intracerebral. The 12-month cumulative incidence of first CRB and MB was 16.6% (95% confidence interval [CI], 13.7-19.6) and 9.1% (95% CI, 6.8-11.3), respectively, in the whole cohort, and 14.4% (95% CI, 11.2-17.5) and 7.0% (95% CI, 4.7-9.2), respectively, in those without anticoagulation. Patients with head and neck cancer had the highest risk of CRB. Lower baseline hemoglobin and albumin were associated with bleeding in patients without anticoagulation. Seven (5.0%) bleeding events were fatal, of which 6 occurred in patients without anticoagulation. Patients with CRB were at an increased risk of all-cause mortality (multivariable transition hazard ratio, 5.80; 95% CI, 4.53-7.43). In patients with cancer, bleeding events represent a frequent complication and are associated with increased mortality.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2024025362","type":"journal-article","created":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T15:49:11Z","timestamp":1724773751000},"page":"2349-2359","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":42,"title":["Bleeding events in patients with cancer: incidence, risk factors, and impact on prognosis in a prospective cohort study"],"prefix":"10.1182","volume":"144","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9007-7738","authenticated-orcid":false,"given":"Cornelia","family":"Englisch","sequence":"first","affiliation":[{"name":"1Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7738-4119","authenticated-orcid":false,"given":"Florian","family":"Moik","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria"},{"name":"2Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4170-603X","authenticated-orcid":false,"given":"Daniel","family":"Steiner","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5867-8461","authenticated-orcid":false,"given":"Angelika M.","family":"Starzer","sequence":"additional","affiliation":[{"name":"3Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9379-6797","authenticated-orcid":false,"given":"Anna S.","family":"Berghoff","sequence":"additional","affiliation":[{"name":"3Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3541-2315","authenticated-orcid":false,"given":"Matthias","family":"Preusser","sequence":"additional","affiliation":[{"name":"3Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7677-9896","authenticated-orcid":false,"given":"Ingrid","family":"Pabinger","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2607-9717","authenticated-orcid":false,"given":"Cihan","family":"Ay","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2024112816205517400_bib1","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/978-3-030-20315-3_13","article-title":"Bleeding disorders associated with cancer","volume":"179","author":"Mantha","year":"2019","journal-title":"Cancer Treat Res"},{"issue":"1","key":"2024112816205517400_bib2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41572-022-00336-y","article-title":"Cancer-associated venous thromboembolism","volume":"8","author":"Khorana","year":"2022","journal-title":"Nat Rev Dis Primers"},{"issue":"14","key":"2024112816205517400_bib3","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood.2020007338","article-title":"Venous thromboembolism in cancer patients: a population-based cohort study","volume":"137","author":"Mulder","year":"2021","journal-title":"Blood"},{"issue":"23","key":"2024112816205517400_bib4","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1093\/eurheartj\/ehab171","article-title":"Relative risk of arterial and venous thromboembolism in persons with cancer vs. persons without cancer-a nationwide analysis","volume":"42","author":"Grilz","year":"2021","journal-title":"Eur Heart J"},{"issue":"5","key":"2024112816205517400_bib5","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.annonc.2022.12.014","article-title":"Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline","volume":"34","author":"Falanga","year":"2023","journal-title":"Ann Oncol"},{"issue":"16","key":"2024112816205517400_bib6","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.23.00294","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO Guideline update","volume":"41","author":"Key","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 2","key":"2024112816205517400_bib7","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/S0049-3848(10)70015-3","article-title":"Bleeding complications associated with anticoagulant therapy in patients with cancer","volume":"125","author":"Trujillo-Santos","year":"2010","journal-title":"Thromb Res"},{"issue":"5","key":"2024112816205517400_bib8","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1253\/circj.CJ-17-1128","article-title":"Anticoagulation therapy for venous thromboembolism in the real world- from the COMMAND VTE Registry","volume":"82","author":"Yamashita","year":"2018","journal-title":"Circ J"},{"issue":"1","key":"2024112816205517400_bib9","doi-asserted-by":"crossref","first-page":"100026","DOI":"10.1016\/j.rpth.2022.100026","article-title":"Atrial fibrillation and cancer: prevalence and relative risk from a nationwide study","volume":"7","author":"Ay","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"issue":"8","key":"2024112816205517400_bib10","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"2024112816205517400_bib11","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer","volume":"380","author":"Khorana","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2024112816205517400_bib12","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1055\/s-0041-1735251","article-title":"Estimating bleeding risk in patients with cancer-associated thrombosis: evaluation of existing risk scores and development of a new risk score","volume":"122","author":"de Winter","year":"2022","journal-title":"Thromb Haemost"},{"issue":"4","key":"2024112816205517400_bib13","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1055\/s-0040-1708481","article-title":"A\u00a0meta-analysis of case fatality rates of recurrent venous thromboembolism and major bleeding in patients with cancer","volume":"120","author":"Abdulla","year":"2020","journal-title":"Thromb Haemost"},{"issue":"4","key":"2024112816205517400_bib14","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"issue":"3","key":"2024112816205517400_bib15","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/jth.12825","article-title":"Estimating risk of venous thromboembolism in patients with cancer in the presence of competing mortality","volume":"13","author":"Ay","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"issue":"446","key":"2024112816205517400_bib16","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A\u00a0proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J\u00a0Am Stat Assoc"},{"issue":"3","key":"2024112816205517400_bib17","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A\u00a0class of K-sample tests for comparing the cumulative incidence of a competing risk","volume":"16","author":"Gray","year":"1988","journal-title":"Ann Statist"},{"issue":"4","key":"2024112816205517400_bib18","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1160\/TH15-09-0758","article-title":"Hypercoagulabilty, venous thromboembolism, and death in patients with cancer. A multi-state model","volume":"115","author":"Posch","year":"2016","journal-title":"Thromb Haemost"},{"issue":"3","key":"2024112816205517400_bib19","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1160\/TH08-02-0125","article-title":"Predicting recurrences or major bleeding in cancer patients with venous thromboembolism. Findings from the RIETE Registry","volume":"100","author":"Trujillo-Santos","year":"2008","journal-title":"Thromb Haemost"},{"issue":"6","key":"2024112816205517400_bib20","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/jth.14007","article-title":"Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study","volume":"16","author":"Kamphuisen","year":"2018","journal-title":"J\u00a0Thromb Haemost"},{"issue":"5","key":"2024112816205517400_bib21","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1055\/s-0038-1641150","article-title":"Renal impairment, recurrent venous thromboembolism and bleeding in cancer patients with acute venous thromboembolism-analysis of the CATCH Study","volume":"118","author":"Bauersachs","year":"2018","journal-title":"Thromb Haemost"},{"key":"2024112816205517400_bib22","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejim.2023.02.003","article-title":"Risk factors for recurrence and major bleeding in patients with cancer-associated venous thromboembolism","volume":"112","author":"Vedovati","year":"2023","journal-title":"Eur J Intern Med"},{"issue":"4","key":"2024112816205517400_bib23","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/rth2.12359","article-title":"Direct oral anticoagulants compared to low-molecular-weight heparin for the treatment of cancer-associated thrombosis: updated systematic review and meta-analysis of randomized controlled trials","volume":"4","author":"Moik","year":"2020","journal-title":"Res\u00a0Pract Thromb Haemost"},{"issue":"4","key":"2024112816205517400_bib24","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1055\/a-2145-7238","article-title":"A\u00a0novel risk prediction score for clinically significant bleeding in patients anticoagulated for venous thromboembolism with active cancer","volume":"124","author":"Cohen","year":"2024","journal-title":"Thromb Haemost"},{"issue":"7","key":"2024112816205517400_bib25","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1016\/S1470-2045(22)00160-7","article-title":"2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19","volume":"23","author":"Farge","year":"2022","journal-title":"Lancet Oncol"},{"key":"2024112816205517400_bib26","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.thromres.2017.08.005","article-title":"Identifying predictors for bleeding in hospitalized cancer patients: a cohort study","volume":"158","author":"Patell","year":"2017","journal-title":"Thromb Res"},{"issue":"1","key":"2024112816205517400_bib27","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/jth.15559","article-title":"Growth differentiation factor-15 for prediction of bleeding in cancer patients","volume":"20","author":"Mulder","year":"2022","journal-title":"J\u00a0Thromb Haemost"},{"issue":"10","key":"2024112816205517400_bib28","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1160\/TH16-12-0946","article-title":"Clinical impact of major bleeding in patients with venous thromboembolism treated with factor Xa inhibitors or vitamin K antagonists. An individual patient data meta-analysis","volume":"117","author":"Bleker","year":"2017","journal-title":"Thromb Haemost"},{"issue":"7","key":"2024112816205517400_bib29","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1108898","article-title":"Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer","volume":"366","author":"Agnelli","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2024112816205517400_bib30","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1055\/s-0042-1758835","article-title":"Survival implications of thrombus recurrence or bleeding in cancer patients receiving anticoagulation for venous thromboembolism treatment","volume":"123","author":"McBane","year":"2023","journal-title":"Thromb Haemost"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/144\/22\/2349\/2316384\/blood_bld-2024-025362-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/144\/22\/2349\/2316384\/blood_bld-2024-025362-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T16:21:14Z","timestamp":1732810874000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/144\/22\/2349\/517583\/Bleeding-events-in-patients-with-cancer-incidence"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,28]]},"references-count":30,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2024,11,28]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024025362","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,28]]}}}